Comparison of angioscopic findings among second-generation drug-eluting stents.
暂无分享,去创建一个
Yasuharu Takeda | Yasunori Ueda | Ayaka Murakami | Y. Higuchi | Y. Yasumura | A. Hirata | Y. Ueda | Y. Nishimoto | K. Kashiwase | Yoshiharu Higuchi | Yuji Nishimoto | Ryuta Sugihara | Keisuke Ueno | Akio Hirata | Kazunori Kashiwase | Yoshio Yasumura | Y. Takeda | Ryuta Sugihara | A. Murakami | Keisuke Ueno
[1] Seiki Nagata,et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. , 2006, Journal of the American College of Cardiology.
[2] A. Hirayama,et al. Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent. , 2006, American heart journal.
[3] D. Balzi,et al. Comparison between drug-eluting and bare metal stent on ST-elevation myocardial infarction outcome: should second-generation drug-eluting stent be preferred? , 2014, Journal of cardiology.
[4] K. Kodama,et al. Atherosclerotic change at one year after implantation of Endeavor zotarolimus-eluting stent vs. everolimus-eluting stent. , 2014, Circulation journal : official journal of the Japanese Circulation Society.
[5] M. Takano,et al. Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent ThrombusCLINICAL PERSPECTIVE , 2008 .
[6] Volker Klauss,et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.
[7] K. Kodama,et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. , 2009, JACC. Cardiovascular imaging.
[8] M. Hori,et al. Serial Angioscopic Evidence of Incomplete Neointimal Coverage After Sirolimus-Eluting Stent Implantation: Comparison With Bare-Metal Stents , 2007, Circulation.
[9] R. Whitbourn,et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. , 2009, JACC. Cardiovascular interventions.
[10] Gregg W Stone,et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. , 2011, Journal of the American College of Cardiology.
[11] T. Hamasaki,et al. Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents. , 2015, Circulation journal : official journal of the Japanese Circulation Society.
[12] T. Akasaka,et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. , 2013, Journal of the American College of Cardiology.
[13] A. Yeung,et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. , 2011, Journal of the American College of Cardiology.
[14] R. Takeshige,et al. Optical coherence tomography study of chronic-phase vessel healing after implantation of bare metal and paclitaxel-eluting self-expanding nitinol stents in the superficial femoral artery. , 2016, Journal of cardiology.
[15] C. Di Mario,et al. First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome , 2002, Circulation.
[16] P. Serruys,et al. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[17] M. Hori,et al. The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up. , 2001, Journal of the American College of Cardiology.
[18] M. Nishino,et al. Comparison of angioscopic findings and three-year cardiac events between sirolimus-eluting stent and bare-metal stent in acute myocardial infarction. , 2011, The American journal of cardiology.
[19] A. Hirayama,et al. Assessment of plaque vulnerability by angioscopic classification of plaque color. , 2004, American heart journal.
[20] Neville Kukreja,et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.
[21] M. Takano,et al. Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus: Angioscopic Comparison Between Paclitaxel- and Sirolimus-Eluting Stents , 2008, Circulation. Cardiovascular interventions.
[22] R. Virmani,et al. Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.
[23] M. Togni,et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial , 2013, The Lancet.
[24] Angioscopic Comparison of Resolute and Endeavor Zotarolimus-Eluting Stents. , 2016, Circulation journal : official journal of the Japanese Circulation Society.
[25] G. Stone,et al. Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial , 2009, Circulation.
[26] M. Nishino,et al. High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: angioscopic comparison with sirolimus-eluting stent. , 2010, American heart journal.
[27] F. Sera,et al. Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents. , 2009, JACC. Cardiovascular interventions.
[28] M. Hori,et al. Angioscopic comparison of neointimal coverage between zotarolimus- and sirolimus-eluting stents. , 2008, Journal of the American College of Cardiology.
[29] Renu Virmani,et al. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. , 2009, JACC. Cardiovascular imaging.
[30] S. Saito,et al. Clinical and angiographic evaluation of the resolute zotarolimus-eluting coronary stent in Japanese patients – long-term outcome in the RESOLUTE Japan and RESOLUTE Japan small vessel study. , 2014, Circulation journal : official journal of the Japanese Circulation Society.
[31] Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy , 2007, Heart.
[32] K. Kodama,et al. Neointimal coverage of stents in human coronary arteries observed by angioscopy. , 1994, Journal of the American College of Cardiology.
[33] Marco Valgimigli,et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.